Abstract
Sickle Cell Anemia (SCA) is the most prevalent genetic disease in world. The lack of new drugs and the low life expectancy are the cruel aspects of the disease. Nowadays, the therapeutic resource include hydroxyurea (HU) and supplementation with glutamine. In vivo, HU is bioconverted in nitric oxide which results in beneficial effects, being the increase in fetal hemoglobin production one…